Literature DB >> 25193964

Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia.

Uwe Platzbecker1, Katja Sockel2, Claudia Schönefeldt2, Daniel Nowak3, Susann Helas2, Christoph Röllig2, Maximilian Mossner3, Johann Christoph Jann3, Gerhard Ehninger2, Wolf-Karsten Hofmann3, Martin Bornhäuser2, Christian Thiede2, Martin Wermke2.   

Abstract

Entities:  

Keywords:  acute myeloid leukemia; eltrombopag; nucleophosmin-1-mutated; refractory; short-term remission

Mesh：

Substances：

Year:  2014        PMID： 25193964      PMCID： PMC4258752          DOI： 10.3324/haematol.2014.111948

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.

Authors:  Ronan Desmond; Danielle M Townsley; Bogdan Dumitriu; Matthew J Olnes; Phillip Scheinberg; Margaret Bevans; Ankur R Parikh; Kinneret Broder; Katherine R Calvo; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

2.  Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.

Authors:  Michael Roth; Britta Will; Guillermo Simkin; Swathi Narayanagari; Laura Barreyro; Boris Bartholdy; Roni Tamari; Constantine S Mitsiades; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2012-05-24       Impact factor: 22.113

3.  Immune suppression for childhood acquired aplastic anemia and myelodysplastic syndrome: where next?

Authors:  Sujith Samarasinghe; Judith Marsh; Carlo Dufour
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

4.  Eltrombopag and improved hematopoiesis in refractory aplastic anemia.

Authors:  Matthew J Olnes; Phillip Scheinberg; Katherine R Calvo; Ronan Desmond; Yong Tang; Bogdan Dumitriu; Ankur R Parikh; Susan Soto; Angelique Biancotto; Xingmin Feng; Jay Lozier; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

5.  Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Britta Will; Masahiro Kawahara; Julia P Luciano; Ingmar Bruns; Samir Parekh; Connie L Erickson-Miller; Manuel A Aivado; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

6.  Eltrombopag: a stem cell cookie?

Authors:  Judith C W Marsh; Ghulam J Mufti
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113
  6 in total
  3 in total

Review 1.  Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.

Authors:  W Li; K Morrone; S Kambhampati; B Will; U Steidl; A Verma
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

2.  Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.

Authors:  Michael Dickinson; Honar Cherif; Pierre Fenaux; Moshe Mittelman; Amit Verma; Maria Socorro O Portella; Paul Burgess; Pedro Marques Ramos; Jeea Choi; Uwe Platzbecker
Journal:  Blood       Date:  2018-10-10       Impact factor: 22.113

3.  The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells.

Authors:  Mingyue Shi; Fangfang Xu; Xiawan Yang; Yanliang Bai; Junwei Niu; Emmanuel Kwateng Drokow; Mingyi Chen; Yuqing Chen; Kai Sun
Journal:  Cancer Manag Res       Date:  2019-09-06       Impact factor: 3.989
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.